Form 8-K - Current report:
SEC Accession No. 0000950170-23-038757
Filing Date
2023-08-07
Accepted
2023-08-07 08:08:30
Documents
14
Period of Report
2023-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rcus-20230807.htm   iXBRL 8-K 59604
2 EX-99.1 rcus-ex99_1.htm EX-99.1 333040
3 GRAPHIC img230044022_0.jpg GRAPHIC 57792
  Complete submission text file 0000950170-23-038757.txt   604991

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rcus-20230807.xsd EX-101.SCH 2457
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rcus-20230807_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rcus-20230807_pre.xml EX-101.PRE 9445
8 EXTRACTED XBRL INSTANCE DOCUMENT rcus-20230807_htm.xml XML 4523
Mailing Address 3928 POINT EDEN WAY HAYWARD CA 94545
Business Address 3928 POINT EDEN WAY HAYWARD CA 94545 (510) 694-6200
Arcus Biosciences, Inc. (Filer) CIK: 0001724521 (see all company filings)

EIN.: 473898435 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38419 | Film No.: 231145720
SIC: 2834 Pharmaceutical Preparations